

## PB 71 of 2023

# National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (August Update) Instrument 2023

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 27 July 2023

#### NIKOLAI TSYGANOV

Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division

Content	S		
	1	Name	1
	2	Commencement	1
	3	Authority	1
	4	Schedules	1
Schedule 1-	—Amo	endments	2
	ional H	ealth (Highly Specialised Drugs Program) Special Arrangement 2021 021)	2

#### 1 Name

- **(1)** This instrument is the National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (August Update) Instrument 2023.
- (2) This instrument may also be cited as PB 71 of 2023.

#### 2 Commencement

Each provision of this instrument specified in column 1 of the table commences, (1) or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information									
Column 1	Column 2	Column 3							
Provisions	Commencement	Date/Details							
1. The whole of this instrument	1 August 2023	1 August 2023							

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

Any information in column 3 of the table is not part of this instrument. (2) Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

### 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

# **Schedule 1—Amendments**

# National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

### [1] Schedule 1, entry for Cinacalcet in the form Tablet 90 mg (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

			Cinacalcet Viatris	C10063 C10067 C10073	56	5	
	Schedule 1, entry for Lanreotide substitute:						
Lanreotide	tide Injection 60 mg (as acetate) in single dose pre-filled syringe	e Injection	Mytolac	C4575 C7025 C7509 C7532 C9260 C9261	2	5	
			Somatuline Autogel	C4575 C7025 C7509 C7532 C9260 C9261	2	5	
	Injection 90 mg (as acetate) in single dose pre-filled syringe	e Injection	Mytolac	C4575 C7025 C7509 C7532 C9260 C9261	2	5	
			Somatuline Autogel	C4575 C7025 C7509 C7532 C9260 C9261	2	5	
	Injection 120 mg (as acetate) in single do pre-filled syringe	se Injection	Mytolac	C4575 C7025 C7509 C7532 C9260 C9261 C10061 C10075 C10077	2	5	
			Somatuline Autogel	C4575 C7025 C7509 C7532 C9260 C9261 C10061 C10075 C10077	2	5	